Background: The difficulties in the identification of C. auris and the delays in the implementation of infection control precautions contribute to outbreaks. This study analyzed 10 patients with COVID-19 and C. auris candidemia, their characteristic and clinical features and phylogenetic features, and the antifungal susceptibilities of the isolates.
Method: C. auris were detected in the COVID-19 ICU of a university hospital between January and August 2021. Identification to species level was performed using MALDI-TOF MS. Antifungal susceptibilities were determined by the Sensititre YeastOne YO10 panel. The isolates were whole genome sequenced to assess genetic relatedness and a phylogenetic tree was drawn including various C. auris clades.
Results: The mean growth time in blood cultures was 38.8 h. C. auris candidemia developed on the average 27th day of ICU admission. All were susceptible to anidulafungin and micafungin, while they were resistant to fluconazole and amphotericin B. Only three isolates were found to be resistant to caspofungin. All patients died. With the WGS method, all isolates were found in a close resemblance to each other in terms of total nucleotide similarity (with a minimum of 96% pairwise alignment). Our isolates showed the closest similarity to South Asian clade (Clade I).
Conclusions: This study is the first to evaluate the phylogenetic characteristics of C. auris using WGS and to determine antifungal susceptibilities in Türkiye on COVID-19 patients. The mortality rate was very high in patients who have both COVID-19 and C. auris candidemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11046-023-00782-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Candidemia chronicles: Retrospective analysis of candidemia epidemiology, species distribution, and antifungal susceptibility patterns in Bahrain.
World J Virol
December 2024
Department of Pediatric, Faculty of Medicine, Tanta University, Tanta 31511, Egypt.
Background: Invasive fungal infections, particularly candidemia, pose significant clinical challenges globally. Understanding local epidemiology, species distribution, and antifungal susceptibility patterns is crucial for effective management despite regional variations.
Aim: To investigate the epidemiology, species distribution, antifungal susceptibility patterns, and associated risk factors of candidemia among patients in Bahrain from 2021 to 2023.
Mortality Patterns in Candidemia: Insights from a Multispecies Analysis Using a Global Research Network.
Med Mycol
December 2024
Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Understanding the impact of different Candida species on patient outcomes is crucial for effective management and treatment strategies. This study aims to comprehensively analyze the association between Candida species and mortality in documented candidemia. We queried TriNetX, a global research network database, to identify patients diagnosed with candidemia through polymerase chain reaction from 2020-2023.
View Article and Find Full Text PDF: Epidemiology Update and a Review of Strategies to Prevent Spread.
J Clin Med
November 2024
Division of Infectious Diseases, Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
Article Synopsis
- Candida auris is a rapidly spreading fungal pathogen that poses serious health risks and has led to considerable illness and death.
- The review highlights current understanding of its epidemiology and effective strategies to prevent its spread and outbreaks.
- Future research directions are also explored to better manage and combat this emerging threat.
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation.
Expert Opin Drug Metab Toxicol
November 2024
Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Introduction: Rezafungin, formerly SP3025 and CD101, is a next-generation echinocandin, chemically related to anidulafungin, with differentiated pharmacokinetic characteristics, including a prolonged half-life allowing extended-interval dosing.
Areas Covered: Herein, we discuss the role of rezafungin in the treatment of candidemia and invasive candidiasis, with a specific focus on pharmacokinetics considerations.
Expert Opinion: Rezafungin exhibits potent in vitro activity against most wild-type and azole-resistant species, including .
fungaemia outbreak in a tertiary care academic hospital and emergence of a pan-echinocandin resistant isolate, Greece, 2021 to 2023.
Euro Surveill
November 2024
Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Article Synopsis
- - After COVID-19 began, there was a significant increase in invasive fungal infections globally, but the specific situation in Greece regarding fungaemias remains unclear.
- - An ongoing outbreak in a Greek hospital has led to 89 episodes of bloodstream infections over nearly three years, with these episodes occurring in waves linked to previous colonization peaks.
- - Most fungal isolates were found to be resistant to fluconazole but sensitive to other antifungals, highlighting the importance of infection control and careful use of antifungal treatments to prevent resistance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!